A message from FACIT President, Dr. David O’Neill
Greetings! The FACIT team is delighted to welcome the new year! For 2024, we maintain our focus on commercializing cancer research and attracting high tech jobs to Ontario. This year, we’ll convene entrepreneurs from across the province at the 11th season of our popular Falcons’ Fortunes pitch competition. We will propel homegrown intellectual property through our Prospects and Compass Rose Oncology Funds for both patient benefit and economic prosperity.
I am confident in the continued success of our unique commercialization venture model, which has recently achieved a remarkable 32x leverage from the private sector and $1.6 billion in follow-on investment into our portfolio of Ontario biotech start-ups. We look forward to working together with our stakeholders and partners to create good-paying jobs, accelerate commercialization and encourage the adoption of Ontario’s innovations to improve health care and grow the economy.
We salute scientific advances and patients everywhere in the battle against cancer. Best wishes for 2024!
Click HERE to read the entire 2024 outlook and 2023 year-in-review newsletter.
PORTFOLIO
FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.
FUNDS
With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.